- 1 **Title:** Blood-based host biomarker diagnostics in active case finding for pulmonary
- 2 tuberculosis: a diagnostic accuracy study

# 3 Authors

- Flora Martinez Figueira Moreira, MS,<sup>1</sup> Renu Verma, PhD,<sup>2</sup> Paulo Cesar Pereira dos Santos, 4
- BS,<sup>1</sup> Alessandra Leite, BS,<sup>1</sup> Andrea da Silva Santos, PhD,<sup>1</sup> Rafaele Carla Pivetta de Araujo, 5
- MS,<sup>1</sup> Bruna Oliveira da Silva, BS,<sup>1</sup> Júlio Henrique Ferreira de Sá Queiroz, MS,<sup>1</sup> David H. 6
- Persing, PhD,<sup>3</sup> Erik Södersten, PhD,<sup>4</sup> Devasena Gnanashanmugam, MD,<sup>5</sup> Purvesh Khatri, 7
- PhD,<sup>2</sup> Julio Croda, PhD,<sup>5,6,7\*</sup> Jason R. Andrews, MD<sup>2,\*</sup> 8

# 9 Affiliations 10

11

12

- 1. Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, MS, Brazil
- 2. Stanford University School of Medicine, Stanford, CA, USA
- 13 3. Cepheid, Sunnyvale, CA, USA
- 14 4. Cepheid AB, Solna, Sweden
- 5. Oswaldo Cruz Foundation, Campo Grande, MS, Brazil 15
- 16 6. School of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, MS, 17 Brazil
- 18 7. Yale School of Public Health, New Haven, CT, USA
- 19 \*Contributed equally

# 20 Correspondence

- 21 Jason Andrews, MD
- 22 **Division of Infectious Diseases and Geographic Medicine**
- 23 Stanford University School of Medicine
- 24 Biomedical Innovations Building, Rm 3458
- 25 240 Pasteur Dr.
- 26 Stanford, CA 94305
- 27 Email: jandr@stanford.edu
- 28 Phone: +1 650 497 2679
- 29
- 30 **Abstract Word Count: 250**
- 31 **Word Count: 3,218**
- 32 Tables: 2
- 33 Figures: 4
- **References:** 28 34

# 35 **Summary**

36 **Background:** There is a need to identify scalable tuberculosis screening strategies among high

- 37 burden populations. The WHO has identified a non-sputum-based triage test as a development 38 priority.
- 39 **Methods:** We performed a diagnostic accuracy study of point-of-care C-reactive protein (CRP) 40 and Xpert-MTB-Host-Response (Xpert-MTB-HR) assays in the context of a mass screening program for tuberculosis in two prisons in Brazil. Incarcerated individuals irrespective of 41 42 symptoms were screened by sputum Xpert-MTB/RIF and sputum culture. CRP was quantified 43 in serum by a point-of-care assay (iChroma-II) and a 3-gene expression score was quantified 44 from whole blood using the Xpert-MTB-HR cartridge. We evaluated receiver operating 45 characteristic area under the curve (AUC) and assessed specificity at 90% sensitivity and 46 sensitivity at 70% specificity, consistent with WHO target product profile (TPP) benchmarks.
- 47 Findings: Two hundred controls controls and 100 culture- or Xpert-positive tuberculosis cases 48 were included. Half of tuberculosis cases and 11% of controls reported any tuberculosis 49 symptoms. AUC for CRP was 0.79 (95% CI: 0.73-0.84) and for Xpert-MTB-HR was 0.84 50 (95% CI: 0.79-0.89). At 90% sensitivity, Xpert-MTB-HR had significantly higher specificity (53.0%, 95% CI: 45.0-69.0%) than CRP (28.1%, 95% CI: 20.2-41.8%) (p=0.003). Among 51 52 individuals with medium or high sputum Xpert semi-quantitative load, sensitivity (at 70% 53 specificity) of CRP (90.3%, 95% CI: 74.2-98.0) and Xpert-MTB-HR (96.8%, 95% CI: 83.3-
- 54 99.9%) was higher.
- 55 Interpretation: For active case finding in this high tuberculosis-burden setting, CRP and 56 Xpert-MTB-HR did not meet TPP benchmarks for a triage test. However, Xpert-MTB-HR was
- 57 highly sensitive in detecting individuals with medium or high sputum bacillary burden.
- 58 Funding: National Institutes of Health (R01 AI130058 and R01 AI149620) and Brazilian
- 59 National Council for Scientific and Technological Development (CNPq-404182/2019-4).
- 60 Xpert-MTB-HR cartridges were provided by Cepheid.
- 61 **Keywords:** tuberculosis; diagnostic; host response; biomarker; triage; active case finding

# 62 Introduction

63

Despite advances in its diagnosis and treatment, tuberculosis (TB) is still the leading cause of 64 65 death among infectious diseases worldwide. It is estimated that 10 million people developed the disease and 1.4 million died from the infection in 2019.<sup>1</sup> Delays in diagnosis of active TB 66 contribute to ongoing transmission of infection and hinder the reduction of disease burden. The 67 68 World Health Organization's "End TB Strategy" proposed a set of actions to reduce the global 69 incidence of TB by 2035, among which are the development of new efficient clinical tools for 70 a fast and accurate diagnosis and systematic screening in high-risk groups to contribute to early 71 detection of the diseases. $^{2-4}$ 

- 72 Timely detection and treatment of cases are central elements in the control of TB transmission. 73 This is particularly critical in high TB risk environments, such as prisons. Globally, prisons
- 74 consistently harbor a very high burden of TB, with rates that are often >30 times higher than
- those of local non-incarcerated communities.<sup>5</sup> Overcrowding, insufficient sanitation, poor 75
- 76 ventilation and inadequate health care in prisons facilitate the spread and persistence of TB and
- 77 other infectious diseases in these environments. In Central and South America, TB notifications
- in prisons have increased by 269% since 2000, driven primarily by growth in the size of the 78
- 79 incarcerated population.<sup>6</sup> Recent studies in Brazil have demonstrated that the prevalence of
- 80 active TB among incarcerated individuals exceeds 3 900 cases per 100 000 persons, among the
- highest reported in the world.<sup>7</sup> There is an urgent need for more effective strategies for early 81
- 82 case detection among high TB burden populations.

83 One of major obstacles to early TB diagnosis is that most approaches depend upon testing of sputum, which individuals with less advanced disease may not consistently produce. In 84 85 response to this challenge, the WHO has endorsed a target product profile (TPP) for a nonsputum based triage test that achieves high sensitivity in screening for active TB.<sup>3</sup> There has 86 87 been considerable effort undertaken to develop and validate blood-based biomarkers for TB, 88 many focusing upon host immune response markers, including metabolomic, proteomic and 89 transcriptomic signatures of disease.<sup>8</sup> Sweeney and colleagues found that a score based on three differentially expressed genes (GBP5, DUSP3 and KLF2) had high accuracy as a screening test 90 for active TB across multiple published cohorts.<sup>9</sup> This signature was subsequently validated 91 92 for diagnosis of TB and prediction of progression from infection to disease in independent cohorts.<sup>10</sup> Based on these findings, Cepheid (Sunnyvale, CA, EUA) developed an assay on 93 94 their Xpert platform, cartridge-based RT-PCR assay (Xpert-MTB-HR) that quantifies the 95 relative mRNA levels of these 3 genes in a whole blood sample. A recent study demonstrated its potential in triage and diagnosis of active TB among people living with HIV and presenting 96 97 to healthcare facilities with TB symptoms.<sup>11</sup> Whether this assay would perform well for active case finding, irrespective of symptoms, in a low HIV prevalence setting is unknown. To address 98 99 this knowledge gap, we performed a diagnostic evaluation study nested within a prospective 100 active TB case finding study in prisons, evaluating the accuracy of a blood based 3-gene

101 signature assay as potential in triage and diagnosis of active TB.

#### 102 **Methods**

## Study design and participants 103

104 This nested diagnostic evaluation study was part of larger prospective mass TB screening study 105 conducted in two prisons (Estabelecimento Penal Jair Ferreira de Carvalho [EPJFC] and 106 Penitenciaria Estadual de Dourados [PED] in Mato Grosso do Sul, Brazil.<sup>7</sup> Between April 2018 and May 2020, we recruited all incarcerated individuals ages  $\geq 18$  years at both study prisons. 107 108 After obtaining informed consent, we administered a standardized questionnaire to collect 109 demographic and clinical information, including TB related symptoms as defined by WHO guidelines.<sup>12</sup> The selection criteria for this study were the collection and availability of a whole-110

- blood sample and at least one spot sputum sample at enrollment. 111
- 112 Laboratory procedures

113 All participants were instructed to produce a sputum sample with a target volume of at least 2 114 mL. Sputum samples were tested at study entry by Xpert MTB/RIF G4 (prior to January, 2020) or Xpert Ultra (after January, 2020; Cepheid, Sunnyvale, CA, USA) along with culture on 115 116 Ogawa-Kudoh media. Whole-blood samples were collected in PAXgene tubes (Becton 117 Dickinson, Franklin Lakes, USA) to preserve RNA and in BD Vacutainer tubes (Becton 118 Dickinson, Franklin Lakes, USA) to obtain serum. PAXgene tubes and serum samples were all 119 collected within 14 days of first sputum sample collection (92% on same day) and were 120 preserved in temperature-controlled freezers at -80°C from collection until testing. C-reactive 121 protein (CRP) concentrations were measured on serum samples with a point-of-care assay (iChroma<sup>™</sup> II, Boditech, South Korea), which has a dynamic range of 2.5-300 mg/L. The 122 123 cartridge-based RT-PCR assay (Xpert-MTB-HR) was performed using 380 uL of PAXgene-124 preserved whole blood. The aliquot was centrifuged, supernatant decanted, and pellet was 125 resuspended in a lysis buffer and vortexed before transfer to the Xpert-MTB-HR cartridge. The 126 samples then were analyzed on a GeneXpert machine, which generates a TB-score calculated 127 from cycle threshold values for the 3-genes according to the formula developed by Sweeney 128 and colleagues.<sup>10</sup> When using PCR-based measurement technology, lower scores by this 129 method have been associated with TB disease. Sample preparation time was 15 minutes and 130 GeneXpert run time was 50 minutes. All participants were administered a rapid HIV test and 131 evaluated through a nursing and medical examination. QuantiFERON-TB Gold Plus assays (QFT-Plus) (Qiagen, Hilden, Germany) were performed among participants without active TB, 132 133 according to the manufacturer's instructions.

134 **Outcome Definitions** 

We followed national Brazilian guidelines and WHO definitions for TB diagnosis. We defined 135 136 a microbiologically confirmed TB case as any individual with a positive sputum Xpert 137 MTB/RIF or sputum culture. Non-microbiologically confirmed (clinically defined) TB cases 138 were not available for inclusion in this study. Controls were defined as individuals with 139 negative sputum Xpert MTB/RIF and culture, who were clinically evaluated and not believed 140 to have active TB disease. All controls had been previously screened within the past year and 141 had a chest x-ray score by CAD4TB < 60. Additionally, we searched the state Sistema de 142 Informação de Agravos de Notificação (SINAN) data, in which all tuberculosis cases are 143 reported, for six months following enrollment to determine whether any of the control 144 participants were subsequently diagnosed with TB. OFT-Plus results were interpreted as 145 positive when IFN- $\gamma$  concentration in the *M. tuberculosis* (*Mtb*) antigen tube was  $\geq 0.35$  IU/mL 146 as defined by the manufacturer.

147 Statistical analysis

148 We compared Xpert-MTB-HR scores and serum CRP concentrations between 149 microbiologically confirmed TB cases and controls, using Wilcoxon sign rank tests for paired samples. We evaluated the linear correlation between Xpert-MTB-HR and CRP concentrations 150 151 among cases and controls. For CRP in linear analyses, values less than 2.5 mg/L (the lower 152 limit of the reporting range) were set as 2.5 mg/L. We also compared Xpert-MTB-HR scores 153 and serum CRP concentrations among cases with controls stratified by QFT-Plus positivity 154 status. We calculated the receiver operating characteristic (ROC) area under the curve (AUC) 155 comparing TB cases and controls for Xpert-MTB-HR and CRP. We compared AUC using 156 DeLong's test. To evaluate performance at WHO benchmarks, we calculated specificity at 90% 157 sensitivity, and sensitivity at 70% specificity, along with 95% confidence intervals. We further investigated the sensitivity according to Xpert MTB/RIF cycle threshold (Ct) value and semi-158 159 quantitative load from sputum samples. This analysis was restricted to cases identified by Xpert 160 MTB/RIF G4, as semiquantitative results and cycle thresholds are different for Xpert Ultra. 161 We examined sensitivity for Xpert MTB/RIF Ct under 28.0, a threshold identified by a recent multi-country study as being 95% sensitive and 54% specific for smear positivity.<sup>13</sup> We 162 163 selected a sample size of 100 cases and 200 controls to achieve precision in 95% confidence 164 interval of < +/-6.5% for the expected sensitivity of 90% and specificity of 70%. All analyses 165 were performed using R, and ROC analyses were performed using the pROC package.<sup>14</sup>

166 Ethical considerations

All participants in the study provided informed consent. This study was approved by Federal 167 University of Grande Dourados, the National Committee on Research Ethics 168 (#44997115.1.0000.5160 and #2.195.047), and the Institutional Review Board and Stanford 169 170 University (#40285). This study conforms to the Standards for Reporting of Diagnostic 171 Accuracy Studies (STARD) reporting guideline.<sup>15</sup>

6

#### 172 **Results**

Between April, 2018 and May, 2020, we screened 4,250 incarcerated individuals in two 173 174 prisons, of whom 1,751 were able to provide sputum for testing. Among these, 131 were 175 positive by sputum Xpert or culture, 1456 were negative by sputum Xpert and culture, and 129 176 were not positive but lacked one of the two assays due to insufficient sputum volume 177 (Appendix Figure A1). From these, we selected consecutive patients for whom baseline serum 178 and PAXgene RNA samples were available and included 100 individuals with microbiologically confirmed TB and 200 individuals who were negative for TB by sputum 179 180 Xpert MTB/RIF, culture, and clinical evaluation.

- 181 Among the 100 TB cases, Xpert MTB/RIF results were available for 96, and 93 (97%) were 182 positive (85 by Xpert G4 [before January, 2020]; 8 by Xpert Ultra [after January, 2020]). Seven 183 cases were identified by culture only. All participants were incarcerated at the time of 184 enrollment, and the median age was slightly younger among TB cases (median age: 31 years, 185 IQR 25, 37) compared with controls (median age: 34 years, IQR 28, 39). A lower proportion 186 of cases self-identified as Indigenous (7% vs 17%; p=0.028). TB cases were more likely to 187 report illicit drug use in the past year (80% vs 50%, p<0.0001), previous incarceration (87 vs 188 54%, p<0.0001), and a known TB contact (82% vs 53%, p<0.0001). Overall, half of TB cases 189 reported any WHO TB symptom, compared with only 11% of controls (p<0.0001). The most 190 common symptom was cough, reported by 45% of cases and 10% of controls. Four individuals 191 with active TB (4%) were HIV co-infected, compared with none of the controls. Among 192 controls, 92 (46%) were QFT-Plus positive (Table 1). Ninety-two percent (276/300) of serum 193 and PAXgene RNA samples were collected on the same day as the first sputum sample 194
- collection and 98% (293/300) were collected within 7 days.
- 195 Compared with controls, TB cases had higher CRP values (9.39 vs <2.5 mg/L; p<0.0001) and 196 lower Xpert-MTB-HR scores (1.69 vs 2.72; p<0.0001) (Figure 1). CRP and Xpert-MTB-HR 197 values were negatively correlated (spearman's rho = -0.44, p<0.0001), and the correlation was 198 much stronger among TB cases (rho= -0.68, p<0.0001) than controls (rho = 0.01, p=0.874) 199 (Figure 2). Area under the curve in distinguishing TB cases from controls was non-200 significantly higher for Xpert-MTB-HR (0.84, 95% CI: 0.79-0.89) than for CRP (AUC 0.79, 201 95% CI: 0.73-0.84; p-value for ROC comparison = 0.105) (Figure 3). At 90% sensitivity, the specificity of CRP was 28.1% (95% CI: 20.2-41.8%) and the specificity of Xpert-MTB-HR 202 203 was 53.0% (33.5-67.0%) (p-value for comparison, 0.003). At 70% specificity, the sensitivity 204 of CRP was 72% (95% CI: 62.1%-80.5%) and sensitivity of Xpert-MTB-HR was 82% (95% 205 CI: 73.1-89.0%) (p-value for comparison, 0.074).

206 Among TB cases, CRP and Xpert-MTB-HR values correlated with sputum semi-quantitative 207 Xpert MTB/RIF G4 values, which are based on PCR cycle thresholds. Compared with TB 208 cases with "very low" MTB quantities, those with "medium" or "high" quantities had higher 209 CRP (median: 20.4 vs <2.5 mg/L; p<0.0001) and lower Xpert-MTB-HR scores (median: 1.06 210 vs 2.20; p<0.0001) (Figure 4a). At the WHO TPP specificity target of 70%, the sensitivities 211 of CRP and Xpert-MTB-HR were strongly correlated with sputum semi-quantitative Xpert 212 MTB/RIF values (Table 2). Among 29 individuals with negative or very low semi-quantitative 213 loads, CRP sensitivity was 44.8% and Xpert-MTB-HR sensitivity was 69.0% (p-value for 214 comparison, 0.111), whereas among the 31 individuals with medium or high semiquantitative 215 loads, CRP sensitivity was 90.3% and Xpert-MTB-HR sensitivity was 96.8% (p-value, 0.612). 216 CRP (spearman's rho, -0.57; p<0.0001) and Xpert-MTB-HR (spearman's rho, 0.54, p<0.0001) values also correlated with sputum Xpert MTB/RIF Ct values (Figure 4b). Among 57 217 participants with sputum Xpert MTB/RIF Ct < 28.0, sensitivity of CRP (at 70% specificity) 218 219 was 81.3% and sensitivity of Xpert-MTB-HR was 89.1%.

- 220 CRP and Xpert-MTB-HR scores did not differ among TB cases with and without symptoms
- (p=0.541 for CRP; p=0.893 for Xpert MTB-HR). Among controls, CRP and Xpert-MTB-HR 221
- values did not differ by QFT-Plus status (p=0.211 for CRP; p=0.802 for Xpert-MTB-HR). 222

#### 223 Discussion

224

225 Active case finding through systematic screening can be an effective means for early detection 226 of TB in high-risk populations, preventing onward transmission. However, performing active 227 case finding effectively and efficiently poses challenges, as diagnostics may not perform well 228 in individuals who have less advanced disease, fewer symptoms, and may be unable to provide 229 adequate sputum samples. To address this need, a target product profile was developed for a 230 non-sputum-based triage test that could achieve high sensitivity (>90%) to identify individuals for further diagnostic evaluation.<sup>3</sup> We tested two candidate triage diagnostics—point-of-care 231 232 CRP and a new gene expression based rapid molecular diagnostic-from blood samples 233 collected during systematic mass screening for TB conducted in two high TB-burden prisons, 234 where we recently reported active TB prevalence of 3 900 per 100 000.<sup>7</sup> We found that both 235 diagnostics had moderate accuracy in distinguishing microbiologically confirmed cases from 236 controls, with Xpert-MTB-HR achieving higher overall accuracy than CRP. At 90% 237 sensitivity, specificity of Xpert-MTB-HR was 53%, the latter falling below the target of 70%. 238 However, both diagnostics had greater sensitivity among individuals with higher MTB burden 239 as measured by Xpert MTB/RIF semi-quantitative load in sputum, suggesting that they may 240 identify individuals with greatest potential for transmission.

A number of studies have evaluated gene expression signatures for identifying individuals with 241 active or incipient TB.<sup>16–19</sup> However, there have been few studies investigating performance of 242 243 these biomarkers in active case finding irrespective of symptoms, and these earlier studies used laboratory-based assays rather than rapid molecular diagnostics.<sup>10</sup> The Xpert-MTB-HR test 244 245 was implemented in a closed system cartridge that quantifies the relative mRNA levels of 3 246 genes in a whole blood sample. Our results corroborate a previous study conducted by 247 Södersten and colleagues in a very different population and clinical setting-screening HIV-248 infected individuals presenting with TB symptoms to clinics in South Africa and Peru-which 249 demonstrated feasibility of measuring the 3-gene signature on this platform.<sup>11</sup> Consistent with 250 this and earlier studies on the 3-gene signature, we found that TB cases had lower Xpert-MTB-HR scores, indicating higher expression levels (up-regulation) of GBP5 and DUSP3 compared 251 with *KLF2*, compared with controls.<sup>9–11,20</sup> The AUC in this study (0.84) was lower than that 252 253 reported by Södersten (0.94 against sputum Xpert MTB/RIF),<sup>11</sup> but consistent with a previous smaller evaluation of the 3-gene signature by laboratory-based qRT-PCR in this low HIV-254 255 prevalence, actively screened population (0.87).<sup>10</sup>

Earlier studies have also investigated CRP testing for distinguishing individuals with active TB 256 257 from those without disease. High accuracy has been reported in some studies of HIV co-258 infected patients,<sup>21,22</sup> though there have been fewer studies assessing screening among HIVnegative individuals, and performance has generally been poorer. A recent study among HIV-259 negative inpatients in Uganda found specificity of 21% at sensitivity of 91%.<sup>23</sup> We are unaware 260 of any studies assessing C-reactive protein in the context of mass screening for active case 261 262 detection. We found the AUC to be 0.79 for the point-of-care CRP test in our study, consistent 263 with the moderate accuracy previously reported in HIV-uninfected individuals. Notably, even 264 among TB cases, the median CRP in our study was substantially lower (9.39 mg/L) than that 265 reported among HIV-infected TB patients in a two previous studies (32.0 mg/L and 51.3 mg/L) by Yoon et al, which used the same device on serum and whole blood samples, respectively. 266 <sup>21,24</sup> Our findings may indicate that HIV-negative individuals have less systemic inflammation 267 268 in the setting of TB, perhaps consistent with the observation that HIV-infected individuals are more likely to have disseminated disease.<sup>25</sup> 269

Neither of the two diagnostics evaluated met the published TPP benchmarks for a non-sputum-270 based diagnostic (>90% sensitivity and >70% specificity);<sup>3</sup> however, the Xpert-MTB-HR 271

9

272 performed better (specificity 53% vs 28%). However, both assays performed well in 273 identifying individuals with medium or high Mtb semiquantitative load in sputum. At 274 specificity of 70%, CRP identified 90% (28/31) and Xpert-MTB-HR identified 97% (30/31) 275 patients with medium/high Mtb semiquantitative sputum Xpert® MTB/RIF result. Sputum Xpert Ct values and semi-quantitative load have been shown to correlate with sputum smear, 276 <sup>13</sup> which in turn has been shown in multiple studies to predict infectiousness.<sup>26,27</sup> It is thereby 277 278 conceivable that both of these diagnostics can reliably identify individuals who have high 279 bacillary burden and are more likely to transmit infection. Further studies are needed to 280 investigate whether these markers indeed identify these high transmission risk individuals, and whether a triage test that identifies such individuals would be useful and cost-effective. 281

282 This study should be interpreted within the context of several limitations. First, all participants 283 were adult men. Our mass screening is focused in male prisons, as only two TB cases were 284 reported in the past year in female prisons, and our prior studies in female prisons demonstrated a very low prevalence of TB in this state.<sup>28</sup> The absence of female representation may have 285 286 reduced the effects of confounding conditions like connective tissue disorders and pregnancy, 287 both of which can lead to CRP elevation. Second, control participants all had chest radiographs 288 with CAD4TB scores <60 one year prior, but this may have led to selection of controls with 289 less lung pathology, limiting generalizability. However, >80% of all individuals in the study 290 prisons have CAD4TB scores <60,<sup>7</sup> suggesting that this group was still representative of the 291 prison population. Third, because this was done within the context of an ongoing mass 292 screening program, we used an older version of Xpert (G4) for the first part of the study and 293 switched to the more sensitive Xpert Ultra when it became available at the site in January, 294 2020; because the Ct values are not comparable between the two cartridges, we only analyzed 295 them for G4, which comprised 91% of the positive Xpert tests. Fourth, it is possible that some 296 of the individuals classified as controls had subclinical or incipient TB that was not detected 297 by sputum Xpert MTB/RIF or culture; we performed one sputum Xpert MTB/RIF and culture 298 on solid media. Using liquid media for culture, performing multiple Xpert tests or cultures, or 299 use of PET-CT could improve classification. However, we note that all treated TB cases in this 300 setting are mandatorily reported in an electronic database, which we reviewed six months after 301 screening; none of the controls were diagnosed with TB in the six months following screening. 302 This reduces the risk that controls were misclassified.

303 There is an urgent need for accurate, rapid tools for screening individuals at high risk of 304 tuberculosis, in order to focus further diagnostic testing and investigations. While Xpert MTB-305 HR outperformed CRP testing in the context of mass screening in a low HIV-prevalence population, it did not meet the WHO target product profile benchmarks for a triage test. These 306 307 findings may be related to the spectrum of disease observed in this setting. Most TB cases in 308 this population had low bacillary burden in their sputum, and half had no symptoms at the time 309 diagnosis, suggesting that mass screening identified them early in their disease course, when 310 they had less systemic inflammation. Among TB cases with medium or high bacillary burden, 311 Xpert-MTB-HR achieved >96% sensitivity at 70% specificity, indicating that it may identify 312 individuals with greater burden of infection and who might be more infectious. Further studies 313 are needed to evaluate its performance for active case finding in other populations, and to 314 determine whether it could be useful for averting transmission in high-risk settings.

# 315 **Contributors**

- 316 FM, RV, JC and JA designed the study. FM, PCPdS, AL, AdSS, RCPdA, BOdS, JHFdSQ collected the data. FM and JA analyzed the data. RV, DHP, ES, DG, PK and JC assisted with 317
- interpretation of the analyses. FM and JA wrote the first draft of the manuscript. All authors 318
- 319 critically revised and approved the manuscript.

# 320 **Declaration of interests**

- 321 PK is a co-inventor on a 3-gene TB score pending patent owned by Stanford University,
- which has been licensed for commercialization. PK is a consultant with Cepheid. DHP, ES, 322
- 323 and DG are employed by Cepheid.
- Data sharing: De-identified data will be made available by the corresponding author upon 324 325 request.

326	Dofe	erences
320 327	Nele	n ences
327	1	World Health Organization. Global Tuberculosis Report 2020. Geneva, 2020
329	1	https://www.who.int/tb/publications/global_report/en/.
330	2	World Health Organization. The End TB Strategy. Geneva, 2014
331	-	https://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1.
332	3	World Health Organization. High-priority target product profiles for new tuberculosis
333	U	diagnostics: report of a consensus meeting. 2014
334		https://apps.who.int/iris/bitstream/handle/10665/135617/WHO_HTM_TB_2014.18_en
335		g.pdf?sequence=1.
336	4	World Health Organization. Systematic screening for active tuberculosis: an
337		operational guide. Geneva: World Health Organization, 2015
338		https://apps.who.int/iris/handle/10665/181164.
339	5	Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis
340		incidence in prisons: a systematic review. PLoS Med 2010; 7: e1000381.
341	6	Walter K, Martinez L, Arakaki-Sanchez, et al. The escalating tuberculosis crisis in
342		Central and South American prisons. In press. Lancet 2020.
343	7	Santos A da S, Oliveira RD de, Lemos EF, et al. Yield, Efficiency and Costs of Mass
344		Screening Algorithms for Tuberculosis in Brazilian Prisons. Clin Infect Dis 2020; : 1–
345		29.
346	8	MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinger CM. A
347		systematic review of biomarkers to detect active tuberculosis. <i>Nat Microbiol</i> 2019; <b>4</b> :
348		748–58.
349	9	Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of
350		pulmonary tuberculosis: a multicohort analysis. Lancet Respir Med 2016; 4: 213–24.
351	10	Warsinske HC, Rao AM, Moreira FMF, et al. Assessment of Validity of a Blood-
352		Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease
353		Severity, and Treatment Response. JAMA Netw Open 2018; 1: e183779.
354	11	Södersten E, Ongarello S, Mantsoki A, et al. Diagnostic accuracy study of a novel
355		blood-based assay # for identification of TB in people living with HIV. J Clin
356		Microbiol 2020; : JCM.01643-20.
357	12	Bone A, Aerts A, Grzemska M, et al. Tuberculosis control in prisons : a manual for
358		programme managers. https://apps.who.int/iris/handle/10665/66823.
359	13	Beynon F, Theron G, Respeito D, et al. Correlation of Xpert MTB/RIF with measures
360		to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of
361		Southern Africa. Sci Rep 2018; 8: 5201.
362	14	Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to
363		analyze and compare ROC curves. <i>BMC Bioinformatics</i> 2011; <b>12</b> : 77.
364	15	Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential
365		items for reporting diagnostic accuracy studies. <i>BMJ</i> 2015; <b>351</b> : h5527.
366	16	Zak DE, Penn-Nicholson A, Scriba TJ, et al. A blood RNA signature for tuberculosis
367		disease risk: a prospective cohort study. <i>Lancet</i> 2016; <b>387</b> : 2312–22.
368	17	Suliman S, Thompson EG, Sutherland J, <i>et al.</i> Four-Gene Pan-African Blood
369		Signature Predicts Progression to Tuberculosis. <i>Am J Respir Crit Care Med</i> 2018; <b>197</b> :
370	10	1198–208.
371	18	Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for
372		tuberculosis diagnosis: A systematic comparison of 16 signatures. <i>PLOS Med</i> 2019;
373 274	10	<b>16</b> : e1002786.
374 375	19	Gupta RK, Turner CT, Venturini C, <i>et al.</i> Concise whole blood transcriptional signatures for incipient tuberculocis: a systematic raview and patient level pooled
513		signatures for incipient tuberculosis: a systematic review and patient-level pooled

376		meta-analysis. Lancet Respir Med 2020; 482: 1–28.
377	20	Francisco NM, Fang Y-M, Ding L, et al. Diagnostic accuracy of a selected signature
378		gene set that discriminates active pulmonary tuberculosis and other pulmonary
379		diseases. J Infect 2017; <b>75</b> : 499–510.
380	21	Yoon C, Semitala FC, Atuhumuza E, et al. Point-of-care C-reactive protein-based
381		tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet
382		Infect Dis 2017; 17: 1285–92.
383	22	Yoon C, Semitala FC, Asege L, et al. Yield and Efficiency of Novel Intensified
384		Tuberculosis Case-Finding Algorithms for People Living with HIV. Am J Respir Crit
385		<i>Care Med</i> 2019; <b>199</b> : 643–50.
386	23	Meyer AJ, Ochom E, Turimumahoro P, et al. C-Reactive Protein for Active
387		Tuberculosis Among Inpatients without HIV in Uganda: A Diagnostic Accuracy
388		Study. J Clin Microbiol 2020; : JCM.02162-20.
389	24	Yoon C, Davis JL, Huang L, et al. Point-of-Care C-Reactive Protein Testing to
390		Facilitate Implementation of Isoniazid Preventive Therapy for People Living With
391		HIV. JAIDS J Acquir Immune Defic Syndr 2014; 65: 551–6.
392	25	Mihret A, Abebe M, Bekele Y, Aseffa A, Walzl G, Howe R. Impact of HIV co-
393		infection on plasma level of cytokines and chemokines of pulmonary tuberculosis
394		patients. BMC Infect Dis 2014; 14: 125.
395	26	Behr M, Warren S, Salamon H, et al. Transmission of Mycobacterium tuberculosis
396		from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444–9.
397	27	Hernandez-Garduno E. Transmission of tuberculosis from smear negative patients: a
398		molecular epidemiology study. Thorax 2004; 59: 286–90.
399	28	Carbone A da SS, Paião DSG, Sgarbi RVE, et al. Active and latent tuberculosis in
400		Brazilian correctional facilities: a cross-sectional study. BMC Infect Dis 2015; 15: 24.
401		

13

# 402 **Tables and Figures**

# 403 Table 1. Sociodemographic and clinical characteristics of incarcerated individuals with and without TB.

Variables	Total N=300 (%)	TB cases N=100 (%)	No TB N=200 (%)	<i>p</i> value	
Median age [IQR]	33 [27, 38]	31 [25, 37]	34 [28, 39]	0.0005	
Ethnicity					
Mixed	155 (52)	50 (50)	105 (52)	0.7141	
White	63 (21)	24 (24)	39 (20)	0.3709	
Black	39 (13)	17 (17)	22 (11)	0.1498	
Indigenous	41 (14)	7 (7)	34 (17)	0.0198	
Asian	2 (1)	2 (2)	0	0.1104	
Less than 8 years of schooling	225 (75)	75 (75)	150 (75)	1	
Current smoker	190 (63)	71 (71)	119 (59)	0.0571	
Illicit drug use over the last year	180 (60)	80 (80)	100 (50)	< 0.0001	
BCG vaccination scar	255 (85)	84 (84)	171 (85)	0.7341	
Previous TB	23 (7)	11(11)	12 (6)	< 0.0001	
Know someone with TB	189 (63)	82 (82)	107 (53)	< 0.0001	
Report any WHO TB symptoms	73 (24)	50 (50)	23 (11)	< 0.0001	
Report cough	66 (22)	45 (45)	21 (10)	< 0.0001	
Previously incarcerated	196 (65)	87 (87)	109 (54)	< 0.0001	
HIV positive	4 (1)	4 (4)	0	0.0118	
QuantiFERON positive	92/200 (46)	NA	92/200 (46)		

404 IQR, Interquartile range. BCG, Bacillus Calmette-Guérin. TB, tuberculosis. WHO, World Health Organization.

# 14

#### 405 Table 2. Sensitivity of C-reactive protein and Xpert-MTB-HR according to sputum Xpert MTB/RIF G4 406 semi-quantitative load and cycle threshold values, using a threshold for specificity of 70%.

Soutum Voort CA regult	n	CRP		Xpert-MTB-HR	
Sputum Xpert G4 result		Positive	% Sens. (95% CI)	Positive	% Sens. (95% CI)
Semi-quantitative load					
Negative/Very Low	29	13	44.8 (26.4-64.3)	20	69.0 (49.2-84.7)
Low	28	21	75.0 (55.1-89.3)	22	78.6 (59.0-91.7)
Medium/High	31	28	90.3 (74.2-98.0)	30	96.8 (83.3-99.9)
Cycle threshold					· · · · ·
≥28.0	31	15	48.4 (30.2-66.9)	21	67.7 (48.6-83.3)
<28.0	57	47	82.5 (70.1-91.3)	51	89.5 (78.5-96.0)
All confirmed cases*	100	72	72.0 (62.1-80.5)	82	82.0 (73.1-89.0)


407 CRP, C-reactive protein. CI, confidence interval. \*Includes 4 culture-confirmed TB cases in whom Xpert semi-quantitative 408 load was not available and 8 cases confirmed by Xpert Ultra.

15

# 409 Figure 1. Distribution of C-reactive protein concentrations (top) and Xpert MTB-HR scores (bottom)


410 among TB cases and controls. CRP: C-reactive protein.






16


#### 414 Figure 2. Correlation between C-reactive protein concentration and Xpert-MTB-HR Score among TB 415 cases and controls, with fitted linear regression lines. CRP: C-reactive protein.



17

# 417 Figure 3. Receiver operating characteristic curves for point-of-care C-reactive protein and the Xpert






18

# 420 Figure 4. C-reactive protein and Xpert MTB-HR scores stratified by sputum Xpert semi-quantitative

421 values (a) and cycle thresholds (b). CRP: C-reactive protein.



Sputum Xpert Ct value

19

### 423 Appendix Figure A1. Flow diagram of study participants in mass screening and selection for

- 424 diagnostic accuracy sub-study.
- 425

